This site is intended for healthcare professionals
Drug news

FDA issues Complete Response Letter for TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia.- Therapeutics MD Inc.

Read time: 1 mins
Last updated:12th Apr 2017
Published:12th Apr 2017
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest